INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:IUI1 • US46120E6023

417.1 EUR
+3.7 (+0.9%)
Last: Feb 10, 2026, 07:00 PM
Fundamental Rating

6

IUI1 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 63 industry peers in the Health Care Equipment & Supplies industry. IUI1 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IUI1 shows excellent growth, but is valued quite expensive already. With these ratings, IUI1 could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • IUI1 had positive earnings in the past year.
  • IUI1 had a positive operating cash flow in the past year.
  • In the past 5 years IUI1 has always been profitable.
  • Of the past 5 years IUI1 4 years had a positive operating cash flow.
IUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFIUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 14.19%, IUI1 belongs to the top of the industry, outperforming 90.48% of the companies in the same industry.
  • IUI1 has a Return On Equity of 16.12%. This is amongst the best in the industry. IUI1 outperforms 82.54% of its industry peers.
  • The Return On Invested Capital of IUI1 (14.47%) is better than 90.48% of its industry peers.
Industry RankSector Rank
ROA 14.19%
ROE 16.12%
ROIC 14.47%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IUI1.DE Yearly ROA, ROE, ROICIUI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • Looking at the Profit Margin, with a value of 28.58%, IUI1 belongs to the top of the industry, outperforming 95.24% of the companies in the same industry.
  • IUI1's Profit Margin has improved in the last couple of years.
  • IUI1's Operating Margin of 29.44% is amongst the best of the industry. IUI1 outperforms 96.83% of its industry peers.
  • IUI1's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 66.38%, IUI1 is in the better half of the industry, outperforming 73.02% of the companies in the same industry.
  • In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
Industry RankSector Rank
OM 29.44%
PM (TTM) 28.58%
GM 66.38%
OM growth 3Y4.46%
OM growth 5Y3.66%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
IUI1.DE Yearly Profit, Operating, Gross MarginsIUI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IUI1 is creating some value.
  • There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IUI1.DE Yearly Shares OutstandingIUI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
IUI1.DE Yearly Total Debt VS Total AssetsIUI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.47
WACC9.82%
IUI1.DE Yearly LT Debt VS Equity VS FCFIUI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • IUI1 has a Current Ratio of 4.97. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
  • IUI1 has a Current ratio of 4.97. This is amongst the best in the industry. IUI1 outperforms 96.83% of its industry peers.
  • A Quick Ratio of 4.20 indicates that IUI1 has no problem at all paying its short term obligations.
  • IUI1 has a better Quick ratio (4.20) than 96.83% of its industry peers.
Industry RankSector Rank
Current Ratio 4.97
Quick Ratio 4.2
IUI1.DE Yearly Current Assets VS Current LiabilitesIUI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.83% over the past year.
  • Measured over the past years, IUI1 shows a very strong growth in Earnings Per Share. The EPS has been growing by 21.42% on average per year.
  • The Revenue has grown by 20.51% in the past year. This is a very strong growth!
  • The Revenue has been growing by 18.22% on average over the past years. This is quite good.
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%

3.2 Future

  • IUI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.07% yearly.
  • The Revenue is expected to grow by 12.31% on average over the next years. This is quite good.
EPS Next Y14.46%
EPS Next 2Y14.31%
EPS Next 3Y14.59%
EPS Next 5Y15.07%
Revenue Next Year15.92%
Revenue Next 2Y14.87%
Revenue Next 3Y14.63%
Revenue Next 5Y12.31%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IUI1.DE Yearly Revenue VS EstimatesIUI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
IUI1.DE Yearly EPS VS EstimatesIUI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

2

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 55.54 indicates a quite expensive valuation of IUI1.
  • Based on the Price/Earnings ratio, IUI1 is valued a bit more expensive than 61.90% of the companies in the same industry.
  • IUI1's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.23.
  • The Price/Forward Earnings ratio is 48.54, which means the current valuation is very expensive for IUI1.
  • Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than the industry average as 69.84% of the companies are valued more cheaply.
  • When comparing the Price/Forward Earnings ratio of IUI1 to the average of the S&P500 Index (28.01), we can say IUI1 is valued expensively.
Industry RankSector Rank
PE 55.54
Fwd PE 48.54
IUI1.DE Price Earnings VS Forward Price EarningsIUI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than 68.25% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of IUI1 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 77.43
EV/EBITDA 48.55
IUI1.DE Per share dataIUI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
  • IUI1 has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as IUI1's earnings are expected to grow with 14.59% in the coming years.
PEG (NY)3.84
PEG (5Y)2.59
EPS Next 2Y14.31%
EPS Next 3Y14.59%

0

5. Dividend

5.1 Amount

  • IUI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

INTUITIVE SURGICAL INC

FRA:IUI1 (2/10/2026, 7:00:00 PM)

417.1

+3.7 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-22
Earnings (Next)04-20
Inst Owners88.29%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap147.86B
Revenue(TTM)10.06B
Net Income(TTM)2.75B
Analysts77
Price Target533.68 (27.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)11.61%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)13.53%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)11%
EPS beat(12)11
Avg EPS beat(12)7.6%
EPS beat(16)13
Avg EPS beat(16)5.75%
Revenue beat(2)2
Avg Revenue beat(2)2%
Min Revenue beat(2)1.84%
Max Revenue beat(2)2.17%
Revenue beat(4)4
Avg Revenue beat(4)2.55%
Min Revenue beat(4)1.09%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)6
Avg Revenue beat(12)0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.31%
PT rev (1m)1.93%
PT rev (3m)2.24%
EPS NQ rev (1m)0.91%
EPS NQ rev (3m)0.91%
EPS NY rev (1m)3%
EPS NY rev (3m)3.32%
Revenue NQ rev (1m)1.05%
Revenue NQ rev (3m)1.08%
Revenue NY rev (1m)1.07%
Revenue NY rev (3m)1.05%
Valuation
Industry RankSector Rank
PE 55.54
Fwd PE 48.54
P/S 18.3
P/FCF 77.43
P/OCF 59.4
P/B 10.32
P/tB 10.53
EV/EBITDA 48.55
EPS(TTM)7.51
EY1.8%
EPS(NY)8.59
Fwd EY2.06%
FCF(TTM)5.39
FCFY1.29%
OCF(TTM)7.02
OCFY1.68%
SpS22.8
BVpS40.42
TBVpS39.59
PEG (NY)3.84
PEG (5Y)2.59
Graham Number82.64
Profitability
Industry RankSector Rank
ROA 14.19%
ROE 16.12%
ROCE 16.61%
ROIC 14.47%
ROICexc 28.65%
ROICexgc 29.85%
OM 29.44%
PM (TTM) 28.58%
GM 66.38%
FCFM 23.63%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y4.46%
OM growth 5Y3.66%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 111.36%
Cap/Sales 7.17%
Interest Coverage 250
Cash Conversion 85.84%
Profit Quality 82.69%
Current Ratio 4.97
Quick Ratio 4.2
Altman-Z N/A
F-Score8
WACC9.82%
ROIC/WACC1.47
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
EPS Next Y14.46%
EPS Next 2Y14.31%
EPS Next 3Y14.59%
EPS Next 5Y15.07%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
Revenue Next Year15.92%
Revenue Next 2Y14.87%
Revenue Next 3Y14.63%
Revenue Next 5Y12.31%
EBIT growth 1Y36.82%
EBIT growth 3Y22.63%
EBIT growth 5Y22.55%
EBIT Next Year34.54%
EBIT Next 3Y22.15%
EBIT Next 5Y20.8%
FCF growth 1Y287.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.61%
OCF growth 3YN/A
OCF growth 5YN/A

INTUITIVE SURGICAL INC / IUI1.DE FAQ

Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?

ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.


Can you provide the valuation status for INTUITIVE SURGICAL INC?

ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.


Can you provide the profitability details for INTUITIVE SURGICAL INC?

INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 8 / 10.


Can you provide the financial health for IUI1 stock?

The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 7 / 10.